ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    corticosteroids | Sickle Cell Disease

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease (IMPROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02061202
Recruitment Status : Recruiting
First Posted : February 12, 2014
Last Update Posted : April 6, 2017
Sponsor:
Information provided by (Responsible Party):
Jeffrey Glassberg, Icahn School of Medicine at Mount Sinai

Brief Summary:
The proposed research is designed to test the global hypothesis that inhaled corticosteroids (ICS), a therapy developed to treat asthma, will prevent vasoocclusive painful episodes in adults with SCD who wheeze, but do not meet criteria for a diagnosis of asthma. The specific aims of this proposal are 1) Conduct a feasibility study - a randomized controlled trial of ICS for adults with SCD who do not meet criteria for a diagnosis of asthma but report recurrent cough or wheezing, 2) Measure the effects of ICS on biological correlates of pulmonary inflammation (as determined by exhaled nitric oxide) and vascular injury (as determined by sVCAM) in SCD, and 3) Compare properties of traditional and Bayesian adaptive clinical trial design for therapeutic trials in SCD in preparation for designing a definitive trial of ICS. These aims have the potential to 1) change the standard of care for individuals with SCD and recurrent cough or wheeze, 2) provide insight into the pathogenesis of non-asthmatic wheezing in SCD and its response to treatment, 3) explore the suitability of innovative clinical trial designs to overcome the challenges that have hindered therapeutic innovation for SCD.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: Mometasone Furoate Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Inhaled Mometasone to Promote Reduction in Vasoocclusive Events
Study Start Date : March 2014
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : November 2017


Arm Intervention/treatment
Experimental: Mometasone Furoate
1 puff daily (220mcg) for 16 weeks
Drug: Mometasone Furoate
inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks

Placebo Comparator: Placebo
1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
Drug: Placebo
placebo training inhaler with the same instructions as the experimental group.




Primary Outcome Measures :
  1. Feasibility [ Time Frame: at 2 years ]
    Feasibility will be determined by calculating the proportion of randomized participants who complete follow up and a minimum of 30 pain diaries with good adherence to the study medication vs. the number enrolled


Secondary Outcome Measures :
  1. Change in Effects of inhaled corticosteroids on pulmonary inflammation [ Time Frame: Before ICS therapy begins and at 8 weeks post enrollment ]
  2. Change in Effects of inhaled corticosteroids vascular injury [ Time Frame: Before ICS therapy begins and at 8 weeks post enrollment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 15 or older
  • Sever SCD phenotypes (Hb SS and Sβthalassemia0)
  • A positive response to cough/wheeze questions

Exclusion Criteria:

  • Patient carries a physician diagnosis of asthma
  • Patient is prescribed asthma medications
  • Patient is currently having a painful crisis (as defined by validated pain diary questions)
  • Patient has acute respiratory symptoms
  • Known hypersensitivity to milk proteins
  • Meets criteria for our operational diagnosis of asthma
  • More than 15 ED visits for pain over the preceding 12 months
  • Admitted or discharged from the hospital for SCD pain within the last 7 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02061202


Contacts
Contact: Alexa Punzalan, BA 212-824-8085 alexa.punzalan@mountsinai.org
Contact: Jeffrey Glassberg, MD, MA 212-824-8056 Jeffrey.Glassberg@mountsinai.org

Locations
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Alexa Punzalan, BA    212-824-8085    alexa.punzalan@mountsinai.org   
Contact: Aria Mattias    212-824-8089    aria.mattias@mountsinai.org   
Principal Investigator: Jeffrey Glassberg, MD, MA         
Sponsors and Collaborators
Jeffrey Glassberg
Investigators
Principal Investigator: Jeffrey Glassberg, MD, MA Icahn School of Medicine at Mount Sinai

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jeffrey Glassberg, Assistant Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT02061202     History of Changes
Other Study ID Numbers: GCO 12-1565
First Posted: February 12, 2014    Key Record Dates
Last Update Posted: April 6, 2017
Last Verified: April 2017

Keywords provided by Jeffrey Glassberg, Icahn School of Medicine at Mount Sinai:
Sickle Cell Disease
Pain Crisis
Painful Crisis
Sickle Pain

Additional relevant MeSH terms:
Anemia, Sickle Cell
Hematologic Diseases
Genetic Diseases, Inborn
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hemoglobinopathies
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents